Abstract
Owing to the increasing number of erythropoietin biosimilars being approved, the comparison of different erythropoietin preparations in the pharmaceutical area is gaining in importance. Erythropoietin has a distinct natural heterogeneity arising from its glycosylation, which shows strong composition variations. This heterogeneity increases the complexity of the analysis of erythropoietin considerably, but may also be used to distinguish different preparations. Here, a method is presented for the differentiation of various erythropoietin preparations by capillary electrophoresis–mass spectrometry and the subsequent application of multivariate statistics. Relative peak areas of selected intact erythropoietin isoforms were used as variables in principal component analysis and hierarchical agglomerative clustering. Both of these strategies were suited for the clear differentiation of all erythropoietin preparations, including marketed products and preproduction preparations, which differ in the manufacturer, the production cell line, and the batch number. By this means, even closely related preparations were distinguished on the basis of the combined information on the antennarity, the sialoform, and the acetylation of the observed isoforms.
Similar content being viewed by others
References
Jacobson LO, Goldwasser E, Fried W, Plzak L (1957) Nature 179(4560):633–634
Sasaki H, Bothner B, Dell A, Fukuda M (1987) J Biol Chem 262(25):12059–12076
Nimtz M, Martin W, Wray V, Kloppel KD, Augustin J, Conradt HS (1993) Eur J Biochem 213:39–56
Takeuchi M, Kobata A (1991) Glycobiology 1(4):337–346
Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rohde MF, Katta V (1995) Anal Chem 67(8):1442–1452
Hokke CH, Bergwerff AA, Van Dedem GW, Kamerling JP, Vliegenthart JF (1995) Eur J Biochem 228:981–1008
Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, Strickland TW (1991) J Biol Chem 266(34):23022–23026
Wasley LC, Timony G, Murtha P, Stoudemire J, Dorner AJ, Caro J, Krieger M, Kaufman RJ (1991) Blood 77(12):2624–2632
Li H, d’Anjou M (2009) Curr Opin Biotechnol 20(6):678–684
Balaguer E, Demelbauer U, Pelzing M, Sanz-Nebot V, Barbosa J, Neusüß C (2006) Electrophoresis 27(13):2638–2650
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) New Engl J Med 316(2):73–78
Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH (1999) Cancer 86(7):1362–1367
Cheer SM, Wagstaff AJ (2004) Drugs 64(3):323–346
Glaspy J, Beguin Y (2005) Oncology 69(Suppl 2):8–16
Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, Burger H-U, Scherhag A (2006) New Engl J Med 355(20):2071–2084
Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z (1985) Proc Nat Acad Sci USA 82(22):7580–7584
Jelkmann W (2003) J Endocrin Invest 26(9):832–837
Catlin DH, Hatton CK, Lasne F (2003) In: Molineux G, Foote M, Elliott S (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser, Basel
Schwenke D, Müller RK (2002) Dtsch Zeitschr Sportmed 53(1):25–26
World Anti-Doping Agency (2010) World anti-doping code. The 2011 prohibited list. International standard. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf. Accessed 18 Jan 2011
Lasne F, Martin L, Crepin N, de Ceaurriz J (2002) Anal Biochem 311:119–126
World Anti-Doping Agency (2009) Harmonization of the method for the identification of recombinant erythropoietins (i.e. epoetins) and analogues (e.g. darbepoetin and methoxypolyethylene glycol-epoetin beta). http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_TD2009EPO_EN.pdf. Accessed 8 Aug 2011
Kohler M, Ayotte C, Desharnais P, Flenker U, Lüdke S, Thevis M, Völker-Schänzer E, Schänzer W (2008) Int J Sports Med 29(1)
Yu N, Ho E, Wan T, Wong A (2010) Anal Bioanal Chem 396(7):2513–2521
Sharpe K, Ashenden M, Schumacher Y (2006) Haematologica 91(3):356–363
Jelkmann W (2009) Curr Med Chem 16(10):1236–1247
Reichel C (2011) Anal Bioanal Chem 401(2):463–481
Roger SD, Mikhail A (2007) J Pharm Pharm Sci 10(3):405–410
Schellekens H (2009) NDT Plus 2(Suppl 1):i27–i36
Jelkmann W (2010) Am J Hematol 85(10):771–780
Brinks V, Hawe A, Basmeleh A, Joachin-Rodriguez L, Haselberg R, Somsen G, Jiskoot W, Schellekens H (2011) Pharm Res 28(2):386–393
Macdougall IC, Ashenden M (2009) Adv Chronic Kidney Dis 16(2):117–130
Neusüß C, Demelbauer U, Pelzing M (2005) Electrophoresis 26(7–8):1442–1450
Balaguer E, Neusüß C (2006) Anal Chem 78(15):5384–5393
Balaguer E, Neusüß C (2006) Chromatographia 64(5):351–357
Taichrib A, Pelzing M, Pellegrino C, Rossi M, Neusüß C (2011) J Proteomics 74(7):958–966
Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J (1998) Br J Haematol 100(1):79–89
Baker M (2008) Use of biosimilar EPO agents widespread at 2008 Tour de France. http://bleacherreport.com/articles/39836-use-of-biosimilar-epo-agents-widespread-at-2008-tour-de-france. Accessed 7 Nov 2011
Erythropoietin. http://en.wikipedia.org/wiki/Erythropoietin. Accessed 7 Nov 2011
Ongay S, Martín-Álvarez PJ, Neusüß C, de Frutos M (2010) Electrophoresis 31(19):3314–3325
Acknowledgments
The authors acknowledge financial support in the course of the announcement “Sicherung der Warenketten” of the Federal Ministry of Education and Research (BMBF) within the scope of the program “Forschung für die zivile Sicherheit” of the Federal Government.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Taichrib, A., Pioch, M. & Neusüß, C. Multivariate statistics for the differentiation of erythropoietin preparations based on intact glycoforms determined by CE-MS. Anal Bioanal Chem 403, 797–805 (2012). https://doi.org/10.1007/s00216-012-5924-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-012-5924-8